An evaluation of the British Pharmacopoeial assay of heparin: a comparison with other methods

GA SHAH, TZ DHALL, I FERGUSON, MR DAVIS, DT GRAHAM, AR POMEROY, AND DP DHALL

From the Vascular Laboratory and Pharmacy, Woden Valley Hospital, Garran, ACT, and the National Biological Standards Laboratory, Canberra, Australia

SUMMARY The potencies of six commercially manufactured heparins have been measured by the British Pharmacopoeial (BP) assay and activated partial thromboplastin time (APTT), protamine sulphate, and anti-Xa assays. The APTT/BP potency ratios were found to vary with the preparation but this was not dependent on the tissue source of heparin. For mucosal heparins, the anti-Xa/BP potency ratios were close to unity, but for heparin of lung origin the anti-Xa potency was approximately one-quarter of the BP potency. Four heparin fractions prepared by column gel chromatography of a commerical heparin were similarly examined by all four assays, and there was a wide divergence between the BP potency estimates and those obtained with the other methods. The degree of divergence was found to depend on the molecular size of the fraction.

Heparin is used widely in low-dose regimes for prophylaxis and in therapeutic doses for the treatment of established venous thromboembolism. In its antithrombotic role, heparin is used to potentiate an anti-Xa action of antithrombin III. The mode of action of heparin as an anticoagulant is less clear, and, when used in this way, the risk of haemorrhage is monitored by clotting assays such as the activated partial thromboplastin time (APTT). As generally marketed, heparin is standardised with a pharmacopeial technique such as the British Pharmacopoeial (BP) assay. Since the activity of commerically manufactured heparin varies with the tissue source of heparin, with the molecular weight composition, and the assay method, the use of one pharmacopeial method to characterise the varying roles of heparin (antithrombotic and anticoagulant) is open to question. In this investigation several heparins manufactured commercially (from lung and mucosa) have been assayed by a variety of techniques to provide information on the adequacy of the BP assay to measure the activity of unfractionated heparins. In addition, heparin fractions separated from one commercial preparation have been similarly examined.

Material and methods

HEPARINS
A bovine mucosal sodium heparin was used as a reference heparin. It was standardised by the BP assay against the Third International Standard Heparin by the National Biological Standards Laboratory, Australia. The specific activity of the reference heparin was found to be 146 units per mg and it was used in assaying the following five mucosal and one lung preparations obtained from various manufacturers.

Heparin of mucosal origin was obtained from:
- Allen and Hanburys (Glaxo Australia)
- 1000 U/ml Batch No 251324 (Boronia, Australia)
- Weddel Pharmaceuticals Limited
- 1000 U/ml Batch No 642A (London, UK)
- Evans Medical Limited
- 1000 U/ml Batch No 5N083A (Liverpool, UK)
- The Boots Company Limited
- 25 000 U/ml Batch No 5456 (Nottingham, UK)
- Commonwealth Serum Laboratories
- 5000 U/ml Batch No 621.02-151/2 (Melbourne, Australia)

Heparin of lung origin was obtained from:
The Upjohn Company
- 10 000 U/ml Batch No 819EX (Michigan, USA)

Received for publication 16 November 1979
HEPARIN ASSAYS
The British Pharmacopoeial assay was modified according to Walton and Wright, and the clotting time endpoint was determined using a coagulometer. This modification of the BP method provides an objective measure of the endpoint and does not alter the potency estimate. The APTT was measured with activated Thrombofax (Ortho Diagnostics, New Jersey, USA) according to the instructions of the manufacturer. The anti-Xa assay was performed according to the method of Denson and Bonnar with a commercially available heparin assay kit (Diagnostic Reagents, Thame, Oxon, UK). In the protamine titration assay, the concentration of protamine sulphate (Boots, Nottingham, UK) was increased in steps of 2 mg/dl (instead of 5 mg/dl) to enhance the sensitivity of the assay. Thrombin (Parke Davis, Detroit, USA) concentrations were chosen to give a thrombin clotting time with unheparinised plasma of 10-12 seconds.

Plasma was prepared from blood obtained from 12 normal blood donors. Blood (9 volumes) was collected into 3.8% sodium citrate (1 volume) and centrifuged at 1300 g for 15 minutes. The platelet poor plasma (PPP) was pooled and stored in vials at -77°C. Heparinised plasma was prepared by adding 1 volume of heparin to 9 volumes of PPP. All clotting assays were performed manually using siliconised glass tubes at 37°C. Plastic or siliconised glassware was used throughout.

Calibration curves with the reference heparin were determined for each method. For the anti-Xa assay a log/linear relationship was established between the clotting time and the concentration of heparin in plasma. A linear relationship was obtained between heparin concentration and the amount of protamine needed to neutralise it. For the APTT assay, a linear relationship between heparin concentration and the clotting time followed an initial non-linear curve. For this assay, test heparin concentrations on the linear portion of the calibration curve were selected.

Using each of the four techniques, heparin activity was determined from the calibration curves in units per ml. To derive specific activity of heparin preparations a metachromatic assay was used to measure the concentration of heparin in mg/ml. In this technique the absorbance at 505 nm of heparin-Azure A mixture was measured with a Unicam SP1800 spectrophotometer. A calibration curve was established with the reference heparin (lyophilised powder), and dilutions of test heparins were chosen to lie where the absorbance at 505 nm linearly related to the concentration of heparin.

HEPARIN FRACTIONATION
Five millilitres of the heparin manufactured by Allen and Hanburys was fractionated by gel filtration on a 2.5 x 45 cm column of medium grade Sephadex G50. The heparin was eluted with distilled water at a flow rate of 36 ml/h. The heparin content in the elution fractions was monitored with a separate metachromatic technique using toluidine blue. For each 1 ml fraction, heparin content was measured by mixing 50 l of the fraction with 3 ml of an aqueous solution of 0.0025% w/v toluidine blue and measuring the transmittance at 500 nm relative to that for known concentrations of the reference heparin preparation. Fractions corresponding to major areas of the elution curve were collected into four pools (Figure) and the specific activity of each pool was determined by the four assays.

Results
The specific activities of all heparin preparations measured by each of the four techniques as well as the coefficient of variation are shown in Table 1a. The coefficient of variation derived from 15 measurements on the Allen and Hanburys heparin preparation is largest for the anti-Xa method and least for the BP assay using the coagulometer. It can be seen that the specific activity varies with the pre-
The ratios are the mean of two measurements except for the Allen and Hanburys heparin where each result is the mean of 15 measurements. The coefficient of variation is derived from the data for the Allen and Hanburys heparin. The heparins are of mucosal origin with the exception of Upjohn heparin, which is of lung origin.

(b) BP potency of each heparin tested expressed as a percentage of the labelled potency (U/ml)

<table>
<thead>
<tr>
<th>Assay method</th>
<th>Allen &amp; Hanburys</th>
<th>Boots</th>
<th>CSL</th>
<th>Weddel</th>
<th>Evans</th>
<th>Upjohn</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>104</td>
<td>91</td>
<td>104</td>
<td>96</td>
<td>107</td>
<td>92</td>
</tr>
<tr>
<td>APTT/BP ratio</td>
<td>1:38</td>
<td>1:10</td>
<td>1:06</td>
<td>1:19</td>
<td>1:36</td>
<td>1:40</td>
</tr>
<tr>
<td>Anti-Xa/BP ratio</td>
<td>0:91</td>
<td>0:98</td>
<td>0:98</td>
<td>1:03</td>
<td>0:89</td>
<td>0:26</td>
</tr>
<tr>
<td>Protamine titration/BP ratio</td>
<td>1:11</td>
<td>1:20</td>
<td>1:05</td>
<td>1:14</td>
<td>1:02</td>
<td>1:11</td>
</tr>
<tr>
<td>Anti-Xa/APTT ratio</td>
<td>0:66</td>
<td>0:89</td>
<td>0:93</td>
<td>0:87</td>
<td>0:66</td>
<td>0:19</td>
</tr>
</tbody>
</table>

The potencies measured with the APTT, anti-Xa and protamine titration assays are expressed as a ratio of the BP potency. The anti-Xa/APTT ratios are also shown.

The specific activities of the four pools obtained by fractionating Allen and Hanburys heparin were determined by the four assays and are shown in the Figure. It can be seen that the specific activities measured for the four pools depend upon the assay method and on the molecular size of the fraction. Table 2 shows the measured potencies for these four pools relative to the BP potency as well as the anti-Xa/APTT ratio. For pool 1 the heparin potency obtained by the BP method is more than twice those obtained by the other methods. For pools 2 and 3, the potency ratios (relative to the BP method) show a marked increase as the molecular size decreases. The anti-Xa/BP ratio showed a further increase in pool 4 while the APTT/BP ratio showed a dramatic decrease. This is reflected in the anti-Xa/APTT ratio which was 2:08 for pool 4 (the smallest molecular size pool) but less than 1 for the other pools.

Discussion

Commercially marketed heparins are assayed against a pharmacopoeial assay. In the investigations described, we have examined six commercial heparins with a variety of assays. Although significant variations were found in the six heparins tested using the BP method, all the measured potencies (including that of the Upjohn heparin, which complies with the requirements of the United States Pharmacopoeia) were within the tolerance limits specified in the British Pharmacopoeia.
An evaluation of the British Pharmacopoeial assay of heparin: a comparison with other methods

Investigations described in this study show that the assigned potency of commercial heparins can vary according to the assay used and that those obtained with the BP assay are not necessarily representative of the values obtained with other methods. The APTT/BP potency ratios varied considerably with the preparation but this was found not to depend on the tissue source of heparin. In four of the six heparins tested, the APTT method gave a higher measurement of heparin than did the BP assay. On the other hand, when the BP assay was compared with the anti-Xa method, good agreement was obtained for the heparins of mucosal origin. For the lung heparin, the potency measured with the anti-Xa assay was found to be markedly reduced. This is reflected in the difference between the anti-Xa/APTT potency ratios for lung and mucosal heparins. It has been shown previously that this ratio was less than 1:0 for lung and greater than 1:0 for mucosal heparin.

Differences between the estimates obtained by the BP method and the other assays were even more pronounced when the various assays were tested against fractions of heparin. Higher potency values of the large molecular size fractions were found using the BP method than with the other methods. Conversely, the small molecular size fractions gave higher assay values with the other methods. The discrepancies between the potency estimates using the BP method and the other clinical methods observed in this investigation may be due in part to the use of animal blood in the BP assay. The anti-Xa/APTT ratio varied with the molecular size of heparin fraction and was dramatically raised in the fraction with the lowest molecular size.

A number of studies have shown that, after parenteral administration, heparin-induced prolongation in the APTT is similar regardless of the tissue source. In contradistinction, the difference between the lung and mucosal heparins in potentiating anti-Xa activity in vitro is also clearly demonstrable in vivo after injection into human subjects.

Since the APTT potencies of the lung and mucosal heparins are similar, both in vitro and in vivo, the large difference in the anti-Xa/APTT ratio between the two sources of heparins originates predominantly in their anti-Xa potencies. This finding may be of some relevance to the current clinical practice of heparin administration in low dosage for its antithrombotic action. It has been assumed that, for optimal antithrombotic prophylaxis, heparin with a high anti-Xa/APTT ratio is more desirable than one with a lower ratio since such a preparation might confer enhanced protection for an equivalent risk of haemorrhage. However, it has been shown in the dog that mucosal heparin causes significantly greater 'delayed haemorrhage' than lung heparin and that protamine reversal is significant only with lung heparin. It seems that only the APTT potency of the two heparins is capable of being reversed completely, and a significant fraction of the initial anti-Xa potency remains unneutralised. It is possible that the unneutralised anti-Xa activity underlies the failure of protamine to reduce effectively the incidence of 'delayed haemorrhage' with heparin of mucosal origin. Thus, the possibility remains that the use of a heparin preparation with a high anti-Xa/APTT ratio may also be associated with an enhanced risk of haemorrhage.

References


Requests for reprints to: Dr DP Dhall, Surgical Unit, Woden Valley Hospital, PO Box 11, Woden, ACT 2606